t TD-1473 represents a potential breakthrough approach to treating ulcerative colitis

baconeggsyum

Regular Member

Joined : May 2010

Posts : 312

Posted 6/9/2016 4:26 PM (GMT 0)

Maybe.. just maybe!!

www.streetinsider.com/Corporate+News/Theravance+Biopharma+%28TBPH%29+Says+TD-1473+Well+Tolerated+in+Phase+1+Clinical+Trial/11724996.html

iPoop

Forum Moderator

Joined : Aug 2012

Posts : 16483

Posted 6/9/2016 5:46 PM (GMT 0)

Hmm a JAK-inhibitor? That's what Xeljanz/Tofacitinib is. A different medication?

DBwithUC

Veteran Member

Joined : Feb 2011

Posts : 4545

Posted 6/9/2016 6:37 PM (GMT 0)

There are several pan-Janus kinase (JAK) inhibitors in the pipeline. But a concern is harm if too much is absorbed systemically.

This initial phase1 trial presents some evidence their JAK is absorbed at much much lower rates.

While it will take years for phase ii and phase iii trials, i would sell stock in Xeljanz/Tofacitinib if I owned any.

✚ New Topic ✚ Reply